ADAMTS-13 levels do not predict outcome in thrombotic thrombocytopenic purpura: Protein S levels are maintained during plasma exchange with solvent detergent treated plasma

被引：0

作者：

Rock, Gail A. ^{[1
]}

Anderson, David ^{[2
]}

Benny, Barrett ^{[3
]}

Barth, David ^{[4
]}

Clark, William ^{[5
]}

Foley, Ronan ^{[6
]}

Sutton, David ^{[4
]}

Leblond, Pierre ^{[7
]}

机构：

[1] Canadian Apheresis Grp, Ottawa, ON, Canada

[2] Queen Elizabeth II HSC, Halifax, NS, Canada

[3] Vancouver Gen Hosp, Vancouver, BC, Canada

[4] Princess Margaret Hosp, Toronto, ON, Canada

[5] Hlth Sci Ctr, London, England

[6] Henderson Gen Hosp, Hamilton, ON, Canada

[7] Hop Enfants Jesus, Quebec City, PQ, Canada

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2895.2895

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2895

引用

页码：852A / 852A

页数：1

共 50 条

[41] Evaluating Patterns in ADAMTS13 Testing and Time to Plasma Exchange Initiation for Suspected Thrombotic Thrombocytopenic Purpura at a County Hospital
Lee, Nicholas C. J.
Bavli, Natalie
Yates, Sean
De Simone, Nicole
Ibrahim, Ibrahim F.
BLOOD, 2021, 138
[42] Microparticles are active components of therapeutic plasma exchange: Correlation with ADAMTS13 activity in patients with thrombotic thrombocytopenic purpura.
Jimenez, Joaquin J.
Jy, Wenche
Mauro, Lucia M.
Lens, Katherine M.
Byrnes, John J.
Shariatmadar, Sherry
Dodson, Hannah J.
Andrews, David
Horstman, Lawrence
Ahn, Yeon-Soong
BLOOD, 2006, 108 (11) : 289A - 289A
[43] ADAMTS13 Helps Distinguish Thrombotic Thrombocytopenic Purpura From Other Microangiopathies and Guide Necessity of Plasma Exchange Therapy
Shah, Neil
Matevosyan, Karen
Burner, James
Sarode, Ravindra
BLOOD, 2011, 118 (21) : 1008 - 1009
[44] Rapid Turnaround ADAMTS13 Testing Is Likely to Improve Diagnosis of Thrombotic Thrombocytopenic Purpura and Avoid Unnecessary Plasma Exchange
McGinnis, Eric
Martin, Spencer D.
Smith, Tyler W.
BLOOD, 2020, 136
[45] Successful management of a Jehovah's witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange
Dabak, Vrushali
Kuriakose, Philip
Raman, Sundara
JOURNAL OF CLINICAL APHERESIS, 2007, 22 (06) : 330 - 332
[46] Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura
Lu, Ruinan
Sui, Jingrui
Zheng, X. Long
BLOOD ADVANCES, 2020, 4 (21) : 5378 - 5388
[47] ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences (vol 4, pg 955, 2006)
Feys, H. B.
Liu, F.
Dong, N.
Pareyn, I
Vauterin, S.
Vandeputte, N.
Noppe, W.
Ruan, C.
Deckmyn, H.
Vanhoorelbeke, K.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (07) : 1651 - 1651
[48] The effect of plasma exchange therapy on von Willebrand factor cleaving protease activity of ADAMTS13 and on autoantibody inhibitor levels in index episodes and relapses of thrombotic thrombocytopenic purpura (TTP).
Böhm, M
Bergmann, L
Betz, C
Scharrer, I
BLOOD, 2002, 100 (11) : 686A - 686A
[49] SOLVENT/DETERGENT-TREATED PLASMA SUPPRESSES SHEAR-INDUCED PLATELET-AGGREGATION AND PREVENTS EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA
MOAKE, J
CHINTAGUMPALA, M
TURNER, N
MCPHERSON, P
NOLASCO, L
STEUBER, C
SANTIAGOBORRERO, P
HOROWITZ, M
PEHTA, J
BLOOD, 1994, 84 (02) : 490 - 497
[50] DETAILED INVESTIGATION OF ADAMTS13 ACTIVITY AND ANTI-ADAMTS13 IGG ANTIBODY LEVELS IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS TREATED WITH CAPLACIZUMAB
Reti, M.
Icleanu, A.
Varkonyi, A.
Kiraly, A.
Bogsch, L.
Farkas, Z.
Remenyi, P.
Prohaszka, Z.
Sinkovits, G.
HAEMOPHILIA, 2023, 29 : 39 - 40

← 1 2 3 4 5 →